IDEAYA Biosciences Inc. and Servier have dosed the first patient in OptimUM-11, a global Phase 3 registrational trial evaluating darovasertib plus crizotinib as adjuvant therapy for people with primary uveal melanoma who have completed local treatment but remain at increased risk of metastatic recurrence. The study is expected to enroll approximately 450 patients irrespective of HLA status and will randomize them equally to receive the oral combination for 12 months or observation, with relapse-free survival serving as the primary endpoint.
The trial expands darovasertib into an important new point in the uveal melanoma treatment pathway. Local treatments such as plaque brachytherapy, radiation and enucleation can control the primary eye tumor effectively, yet a substantial proportion of patients eventually develop metastatic disease, most frequently involving the liver. There is currently no approved systemic adjuvant treatment specifically established to prevent that recurrence after successful local treatment of the primary tumor.
OptimUM-11 therefore tests whether intervening before clinically detectable metastases emerge can alter the natural history of the disease. That is a considerably different question from the metastatic setting, where IDEAYA Biosciences and Servier have already reported a significant progression-free survival benefit from darovasertib plus crizotinib. Patients entering the adjuvant study may have no detectable cancer after local therapy, which raises the evidence and safety standards for exposing them to a year of systemic treatment.
Why does the Phase 3 OptimUM-11 trial address one of uveal melanoma’s biggest treatment gaps?
Uveal melanoma develops from melanocytes inside the eye and is biologically distinct from the more common cutaneous form of melanoma. Primary tumors can frequently be controlled with localized radiation or surgery, but local control does not eliminate microscopic cancer cells that may already have escaped from the eye before treatment.
IDEAYA estimates that as many as half of patients with primary uveal melanoma ultimately develop metastatic disease. Once metastasis occurs, the prognosis becomes substantially more difficult, with the liver involved in the overwhelming majority of cases. Preventing or delaying that transition consequently represents one of the largest remaining therapeutic opportunities in the disease.
Adjuvant treatment is conceptually attractive because tumor burden should be lowest immediately after definitive local therapy. If microscopic metastatic deposits remain, targeting them before they establish clinically measurable disease could theoretically produce more durable control than waiting until radiographic metastases appear.
The challenge is proving that systemic treatment changes outcome rather than simply exposing patients to toxicity earlier. Patients randomized to observation in OptimUM-11 have already completed treatment for their visible primary tumor and may remain recurrence-free for years without additional therapy. Darovasertib plus crizotinib therefore needs to create a sufficiently large improvement in relapse-free survival to justify treating the entire high-risk population.
Risk selection will consequently be critical. The study is enrolling patients classified as having increased metastatic risk rather than every person with uveal melanoma. Molecular, pathological and clinical features can identify populations with substantially different probabilities of recurrence, allowing a trial to concentrate on patients most likely to derive meaningful absolute benefit from systemic intervention.
What does the metastatic OptimUM-02 study tell us about the darovasertib combination?
The strongest clinical evidence supporting the combination comes from OptimUM-02, a Phase 2/3 registrational study in previously untreated HLA-A*02:01-negative metastatic uveal melanoma. In that setting, darovasertib plus crizotinib significantly improved progression-free survival compared with investigator-selected treatment.
The study included 313 patients, with approximately twice as many randomized to the darovasertib combination as to the control arm. Blinded independent central review found median progression-free survival of 6.9 months with darovasertib plus crizotinib compared with 3.1 months for investigator’s choice, producing a hazard ratio of 0.42 and corresponding to a 58% reduction in the risk of disease progression or death during the measured period.
Response rates also favored the targeted combination. The objective response rate was 37.1% compared with 5.8% in the control group, while disease control was reported in 73.3% versus 31.1%, respectively. Those data have supported IDEAYA’s ongoing New Drug Application process for the metastatic indication.
The metastatic study provides genuine evidence that simultaneously targeting PKC and cMET can suppress established uveal melanoma. It does not demonstrate that the same combination will prevent recurrence after treatment of localized disease. Metastatic tumors provide measurable lesions against which response can be assessed, whereas adjuvant treatment targets microscopic disease that cannot be directly observed.
The treatment threshold also differs. Patients with metastatic cancer have active life-threatening disease and relatively limited systemic options, allowing a greater tolerance for treatment-related adverse events. Patients in an adjuvant study may feel well and have no detectable metastases, so chronic toxicity, dose interruptions and quality-of-life effects carry greater significance.
Why are PKC and cMET rational targets in uveal melanoma biology?
Most uveal melanomas are driven by activating alterations affecting GNAQ or GNA11, which trigger downstream signaling that includes protein kinase C. Darovasertib is an oral small-molecule inhibitor designed to suppress PKC isoforms involved in this oncogenic signaling cascade, placing the drug relatively close to a core molecular driver of the disease.
Crizotinib inhibits several kinases, including cMET. Combining the two drugs is intended to block complementary pathways that support uveal melanoma growth and survival. The marked progression-free survival and response-rate differences in OptimUM-02 provide clinical support for the combination strategy in established metastatic disease.
This disease biology is also why IDEAYA is trying to develop darovasertib across multiple treatment stages rather than restricting it to one metastatic indication. The company is evaluating the drug in metastatic, neoadjuvant and now adjuvant settings, effectively building a franchise around inhibition of the same central signaling pathway at different points in the patient’s treatment journey.
OptimUM-11 is intentionally HLA agnostic. That is commercially and clinically important because another major treatment approach in metastatic uveal melanoma depends on HLA status. A targeted therapy that functions irrespective of HLA type could potentially address a wider population if the clinical evidence supports use.
The lack of an HLA restriction does not mean every patient will benefit equally. Tumor genetics, metastatic-risk features and other biological variables may influence treatment sensitivity, and the Phase 3 dataset could eventually help identify subgroups with different absolute benefits.
Why is relapse-free survival the decisive endpoint for an adjuvant uveal melanoma treatment?
Relapse-free survival measures how long patients remain alive without recurrence after treatment intended to eradicate visible disease. In the adjuvant setting, it provides a practical endpoint because waiting for mature overall survival results in a rare cancer could require many additional years and a much larger study.
A statistically significant improvement would indicate that the combination delays or prevents recurrence compared with observation. The magnitude of that improvement will matter enormously because the treatment period lasts 12 months and exposes patients who may never otherwise have relapsed during that interval.
A small numerical difference may not be sufficient to change practice if toxicity, monitoring requirements or treatment burden are substantial. Conversely, a large reduction in metastatic recurrence could fundamentally change management because clinicians currently lack an approved systemic intervention to offer high-risk patients after local therapy.
Longer follow-up will remain important even if the primary endpoint succeeds. Adjuvant therapy can sometimes delay recurrence without ultimately changing overall survival if relapses occur later. Investigators will need to understand whether separation between the treatment and observation groups persists after therapy ends.
The pattern of recurrence could also be informative. Because liver metastasis dominates the clinical course of uveal melanoma, the trial may ultimately provide insight into whether systemic PKC and cMET inhibition changes the timing or distribution of metastatic disease.
What safety standard must darovasertib plus crizotinib meet in disease-free patients?
OptimUM-02 characterized the combination’s safety profile as manageable in metastatic disease, with relatively low rates of treatment-related serious adverse events and treatment discontinuations attributed to darovasertib. That experience is reassuring, but it cannot simply be transferred to an adjuvant population.
Adjuvant patients start treatment from a fundamentally different position. They have no confirmed metastatic disease and may be able to remain well for a prolonged period without systemic therapy. Even moderate chronic adverse effects can therefore weigh heavily in the benefit-risk calculation.
The 12-month treatment duration creates additional importance around adherence. Frequent dose reductions or discontinuations could reduce efficacy while undermining the practical attractiveness of preventive therapy. IDEAYA and Servier will therefore need to demonstrate not only that the regimen delays recurrence, but that a substantial proportion of patients can complete the planned treatment course.
Quality-of-life assessment should also be valuable. Preventing metastasis is an enormously important goal, but a therapy intended for otherwise asymptomatic patients needs a clear understanding of how fatigue, gastrointestinal effects, edema or other treatment-related symptoms affect daily life.
Commercial adoption after any eventual approval would likely be strongest in patients with the highest predicted metastatic risk, where the absolute potential benefit is greatest. Risk stratification could therefore become central to the real-world treatment algorithm even if the regulatory label is broader.
How does OptimUM-11 fit into IDEAYA Biosciences’ wider darovasertib regulatory strategy?
IDEAYA is simultaneously attempting to establish darovasertib across much of the uveal melanoma treatment continuum. The company has initiated an NDA submission for darovasertib plus crizotinib in first-line HLA-A*02:01-negative metastatic uveal melanoma under the FDA Oncology Center of Excellence Real-Time Oncology Review program and expects to complete that submission during the second half of 2026.
Darovasertib also carries Fast Track designation in metastatic uveal melanoma, Orphan Drug designation in primary uveal melanoma and Breakthrough Therapy designation for neoadjuvant use in patients with primary disease for whom removal of the eye has been recommended. These designations do not constitute approval but illustrate how broadly IDEAYA is pursuing the molecule.
A successful metastatic launch could give the company commercial infrastructure, physician familiarity and real-world safety experience before OptimUM-11 reaches maturity. Success in the adjuvant setting would then substantially expand duration of treatment and the number of potentially eligible patients.
Servier’s partnership reduces the geographic commercialization burden. IDEAYA retains regulatory and commercial rights in the United States, while Servier holds rights outside the United States, and the partners share development costs associated with the program.
IDEAYA also has considerable financial capacity to support its portion of development. The company reported approximately $1.24 billion in cash, cash equivalents and marketable securities at June 30, 2026 following a large equity financing, providing a substantial runway as multiple late-stage oncology programs advance.
What does IDEAYA’s share price indicate after the Phase 3 start?
IDEAYA Biosciences shares closed at approximately $37.59 on September 11, compared with $38.35 when the OptimUM-11 first-patient announcement was released on September 9. The modest decline suggests investors treated trial initiation as an expected execution milestone rather than a new clinical catalyst.
That interpretation is reasonable because the OptimUM-11 design had already been disclosed and had been discussed with the FDA before the first patient was enrolled. Investor attention remains more immediately focused on the metastatic darovasertib regulatory submission, additional uveal melanoma data and the company’s broader oncology pipeline.
The shares nevertheless remain well above levels seen earlier in the year and within striking distance of their recent 52-week high, reflecting stronger sentiment following the successful OptimUM-02 metastatic study and progress across the pipeline. Future valuation will increasingly depend on whether darovasertib evolves from a promising metastatic asset into a multi-setting franchise.
OptimUM-11 may ultimately be the most ambitious part of that strategy. The company is moving from treating measurable metastatic cancer to trying to stop metastasis before it becomes detectable, a setting where clinical benefit could be profound but the evidence standard is correspondingly higher. If 12 months of darovasertib plus crizotinib materially extends relapse-free survival without imposing excessive toxicity, IDEAYA Biosciences and Servier could establish the first systemic adjuvant treatment paradigm in primary uveal melanoma. If the trial fails, it would reinforce an important oncology lesson: activity against established metastatic disease does not automatically mean the same therapy can eradicate microscopic residual disease.
